| BRIEF REPORT |
|
| Year : 2020 | Volume
: 4
| Issue : 5 | Page : 101-103 |
|
|
Is ivermectin–Azithromycin combination the next step for COVID-19?
Hayder Mutter Al-Kuraishy1, Nawar Raad Hussien1, Marwa Salih Al-Naimi1, Ali Kadhem Al-Buhadily1, Ali Ismail Al-Gareeb1, Claire Lungnier2
1 Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
2 Department EA 3072 “Mitochondria, Oxidative Stress and Muscular Protection”, Institute of Physiology, Faculty of Medicine, Strasbourg Cedex, France
Correspondence Address:
Prof. Hayder Mutter Al-Kuraishy
Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty College of Medicine, Al-Mustansiriya University, P.O. Box 14132, Baghdad
Iraq
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/bbrj.bbrj_109_20
|
|
|
Different experimental and approved drugs were tested for coronavirus infection disease (COVID-19) to detect effective one that attenuates or prevents the pathogenesis of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Repurposing of old approved drugs with the potential arrhythmogenic effect such as chloroquine in COVID-19 may increase the risk of sudden cardiac death due to torsadogenic potential. The Food and Drug Administration approved the drugs, such as ivermectin, which can kill SARS-CoV-2 within 48 h. Azithromycin augments the antiviral activity of chloroquine in COVID-19 with a high risk of morbidity and mortality through torsadogenic potential. There were no obvious interactions between ivermectin and azithromycin and without risk of torsadogenic effect despite the prolongation of QT by azithromycin. Therefore, azithromycin–ivermectin is regarded as an effectual combo for COVID-19 in elderly patients with underlying cardiac abnormalities.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
